People across the world are waiting with bated breath for the COVID-19 vaccine. Countries imposed lockdowns and strict social distancing rules to stem the spread of the virus since March this year which has impacted business and economy. Which is why many people are pinning their hopes on a vaccine as the only way to get back to pre-corona life. As the cost of herd immunity would be millions of lives and no nation wants to afford it.
Researchers around the world are working on 165 different vaccines out of which, 24 have moved onto clinical trials as notified by WHO on 21st July. The one who develops the first vaccine is not going to be the only winner of this race to find a corona vaccine, as no one vaccine would be enough to inoculate the entire world’s population for the coronavirus.
These 24 vaccine candidates, across at least ten countries, are already undergoing clinical trials. Developing a successful vaccine is just the start of the battle. We will also need the vaccine in adequate numbers to meet the needs of everyone.
Pfizer has said that the U.S. government had already placed an initial order of 100 million doses for $1.95 billion with it. They also said that the US government can acquire up to 500 million additional doses
In the address, they explained that the American brand will work in collaboration with German brand BioNtech to give all Americans the vaccine for free with the U.S. government’s commitment to access COVID-19 vaccines for free.
The company also assured that they will remain on track to begin a safety and efficacy trial later this month, seek regulatory review as early as October 2020, and manufacture globally up to 100 million doses by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021.
According to the list released by the WHO on July 21, China’s Sinovac is developing a vaccine which is currently under clinical phase- III. Thus, an Indonesian company Bio Farma has decided to produce 100 million doses of the Covid-19 vaccine once the final stage of clinical tests of this vaccine is completed. The vaccine is being developed by China in collaboration with Brazil and will be produced on a mass level.
China’s Sinovac Biotech is working in collaboration with Instituto Butantan (
Brazil) who is currently conducting Phase 3 clinical trials in Brazil. Indonesia will also work with Sinovac in the Phase 3 trials involving 1,620 volunteers. Indonesian State-run pharmaceutical company Bio Farma has set a plan to produce 100 million doses of Covid-19 vaccine once the final stage of clinical tests is completed
Earlier, On July 10 Moderna Inc had signed an agreement with Spain’s Laboratory pharmaceutical ROVI SA to scale up the manufacturing and production of its potential COVID-19 vaccine for countries other than the United States. Spain’s pharmaceutical company will begin a new production line and arrange equipments for vital filling and packaging, automatic visual inspection and labeling, and hire more staff to support the production of millions of doses of Moderna’s vaccine candidate.
Talking about AstraZeneca which is working in partnership with the University of Oxford to produce a vaccine. In the latest move, the company with the Serum Institute of India (SII) and other vaccines producers across the world had agreed to mass-produce the vaccine on a large scale.
Phase II/ III trial of the vaccine will take place with 10,000 volunteers in different countries around the world.
“In addition, the university and industry partnership reached a licensing agreement with Serum Institute of India to supply one billion doses for low-and-middle-income countries including India, with a commitment to provide 400 million before the end of 2020”, officials from the oxford university said.The agreements were made under a not-for-profit motive.
AstraZeneca individually will also be supplying 400 million doses to the US and UK. The company is building several supply chains in parallel across the world and till now has secured manufacturing capacity for two billion doses of the vaccine.
Apart from this, the Gavi, vaccine alliance, and the Coalition of Epidemic Preparedness Innovations (run by Bill and Melinda Gates Foundation) sealed a $750 million deal to support the manufacturing and distribution of 300 million doses of the vaccine, with delivery starting by the end of the year, 2020. This agreement will bring the vaccine to India and low-income countries.
Click here for Latest News updates and viral videos on our AI-powered smart news
For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us onInstagram